PeptideDeepDiveWhat Is NAD+? NMN, NR & IV Therapy Evidence Explained
NAD+ is a core cellular coenzyme, but NAD+ supplements, oral precursors such as NMN and NR, and IV NAD+ therapy do not share the same evidence base. This guide separates biomarker changes from proven health outcomes and explains what human trials actually show.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that cells use in energy metabolism, redox reactions and enzyme signalling. Human trials show that oral precursors such as NR and NMN can raise circulating NAD+-related biomarkers. However, raising a biomarker has not been shown to extend human lifespan, and a 2026 systematic review found no eligible outcome trials of IV or IM NAD+ for anti-aging or wellness.
The PeptideDeepDive Editorial Team checks major claims against randomized trials, systematic reviews and official FDA material. Importantly, we separate evidence for oral precursors from evidence for IV/IM NAD+ and distinguish NAD+ biomarker changes from proven clinical outcomes. We have not added a medical reviewer credential because no verified clinician reviewer was provided. This page is educational only and does not provide dosing or treatment advice.
What Is NAD+ and Why Do People Use NAD+ Precursors?
NAD+ (nicotinamide adenine dinucleotide) is not a peptide. It is a vitamin-B3-derived coenzyme used across cellular energy metabolism, redox reactions, DNA-repair pathways and enzyme signalling. NAD biology changes with age and disease in complex, tissue-specific ways. Notably, a 2026 Nature Metabolism study found that whole-blood NAD+ levels remained stable across age groups, which challenges the idea that one blood NAD+ measurement is a simple aging biomarker.
Most human supplementation research therefore focuses on NAD+ precursors rather than on oral NAD+ itself. The two best-known precursors are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which feed into NAD+ biosynthesis. In contrast, wellness clinics may offer NAD+ directly by IV or IM routes, even though that approach has a much thinner clinical evidence base.
Oral NAD+ Precursors vs IV NAD+: Different Evidence Entirely
The route and compound matter. Oral NR and NMN have multiple human intervention studies, while direct IV/IM NAD+ has far less outcome evidence for anti-aging or wellness claims.
A 2026 systematic review identified 33 human intervention studies, including 28 randomized trials, across NAD+-related compounds. Oral NR and NMN consistently showed biochemical target engagement and were generally well tolerated over weeks to months, although health outcomes were mixed.
The same review found no eligible outcome trials evaluating IV or IM NAD+ itself for anti-aging or wellness. FDA has also warned compounders about sterility risks when unsuitable food-grade NAD+ ingredients are used to make sterile IV products.
What Do NAD+ Trials Actually Show?
A randomized 2026 Nature Metabolism study directly compared NAD+ boosters in 65 healthy participants. After 14 days, NR and NMN each raised baseline whole-blood NAD+ by about two-fold compared with placebo, while nicotinamide did not produce the same sustained effect. Read the randomized precursor comparison.
However, biochemical target engagement is not the same as a proven longevity benefit. A 2026 PRISMA-guided systematic review identified 113 eligible studies: 33 human interventions and 80 rodent studies. In people, oral NR and NMN reliably changed NAD+-related biomarkers, but effects on metabolic, vascular, functional and other healthspan outcomes were mixed, often null or specific to certain endpoints. See the 2026 systematic review.
A 2024 meta-analysis of 12 randomized NMN trials involving 513 adults also found that NMN raised blood NAD levels. However, most measured metabolic outcomes did not show a clear advantage over placebo, although triglycerides showed a modest improvement. Read the NMN meta-analysis.
Are NAD+, NMN and NR Safe?
Short-term oral NR and NMN studies generally report good tolerability, but most trials last weeks or months rather than years. Therefore, long-term safety and long-term clinical benefit remain less certain. Product quality also matters because supplement manufacturing and labeling can vary between sellers.
IV NAD+ adds a separate sterile-compounding risk. FDA has specifically warned compounders not to use food-grade NAD+ ingredients to make sterile injectable products without appropriate processing because microbial and endotoxin contamination can harm patients. See the FDA sterile-compounding warning.
What Is the Regulatory Status of NAD+, NMN and NR?
Dietary supplements are not FDA-approved for safety or effectiveness before sale. NR and NMN can appear in supplement products, but that does not make them FDA-approved anti-aging treatments. NMN has had a particularly complex US regulatory history; FDA’s current public records show a beta-NMN New Dietary Ingredient notification (NDIN 1444) with an FDA response dated January 28, 2026. An NDI response is not drug approval.
Injected NAD+ sits in a different category. FDA has taken enforcement action against firms repackaging or compounding NAD+ injections without meeting applicable drug requirements. In a February 2026 warning letter, FDA described NAD+ 50 mg/mL injections sold by one firm as unapproved new drugs. That does not mean every clinical use is identical, but it does show that “available at a clinic” is not the same as “FDA-approved for longevity.”
For FDA’s general supplement framework, see FDA 101: Dietary Supplements. For the current NMN notification record, see FDA’s submitted NDI notifications.
What Is Still Unknown About NAD+ Boosters?
- Whether reliable increases in NAD+-related biomarkers translate into meaningful, repeatable improvements in long-term health or lifespan
- Which populations, if any, gain clinically meaningful benefit from NR or NMN beyond changes in laboratory biomarkers
- Long-term safety over years rather than weeks or months
- Whether IV or IM NAD+ provides any anti-aging or wellness benefit that oral precursor studies have not already addressed
- How useful blood NAD+ is as an aging biomarker, especially after 2026 data found no clear age-related decline in whole blood
Overall, NAD+ precursor research is further along than most unapproved research compounds discussed on this site. However, the strongest human evidence currently supports a narrower claim: NR and NMN can raise NAD+-related biomarkers. That is not the same as proving that NAD+ boosters slow aging, extend lifespan or improve every health outcome. The evidence gap is especially large for IV/IM NAD+ anti-aging claims.
NAD+ FAQ
Do NMN and NR actually raise NAD+ in humans?
Yes. A 2026 randomized study found that 14 days of oral NR or NMN increased baseline whole-blood NAD+ by about two-fold compared with placebo. However, a biomarker increase does not prove a longevity or health benefit.
What is the difference between NMN and NR?
NMN and NR are different vitamin-B3-related precursors that feed into NAD+ metabolism. Human studies show that both can raise circulating NAD+-related biomarkers, but they use different metabolic routes before reaching the NAD+ pool.
Is IV NAD+ therapy evidence-based?
Evidence is much thinner than for oral precursors. A 2026 systematic review found no eligible outcome trials of IV or IM NAD+ itself for anti-aging or wellness, so common clinic claims go beyond the current outcome evidence.
Are NAD+ precursors safe?
Short-term human trials generally report that oral NR and NMN are well tolerated. However, long-term safety over years is not established, and supplement quality can vary.
Do NAD+ supplements extend human lifespan?
No human trial has shown that NR, NMN or IV NAD+ extends lifespan. Current human evidence is stronger for biomarker changes than for proven anti-aging outcomes.
Does NAD+ always decline with age?
The picture is more complicated than common marketing claims suggest. NAD biology changes with age in some tissues and disease states, but a 2026 Nature Metabolism study found that whole-blood NAD+ levels did not decline with age across several human cohorts.
References
- Christen, S. et al. (2026), The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans, Nature Metabolism — randomized comparison of NR, NMN, nicotinamide and placebo.
- Gallagher, C. and Emmanuel, O.O. (2026), NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence, Ageing Research Reviews — 113 studies, including 33 human interventions and no eligible IV/IM NAD+ outcome trials for anti-aging/wellness.
- Liao, B. et al. (2024), Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults — meta-analysis of 12 randomized trials with 513 participants.
- Trętowicz, M.M. et al. (2026), Human whole-blood NAD+ levels do not vary with age or lifestyle interventions, Nature Metabolism — challenges whole-blood NAD+ as a simple biomarker of aging.
- U.S. Food and Drug Administration, FDA reminds compounders to use ingredients suitable for sterile compounding — specifically discusses food-grade NAD+ being used to make IV products and contamination risk.
- U.S. Food and Drug Administration (2026), Thrive Health and Wellness warning letter — includes NAD+ 50 mg/mL injections described as unapproved new drugs at that firm.
- U.S. Food and Drug Administration, Submitted 75-Day Premarket Notifications for New Dietary Ingredients — current public record includes beta-NMN notification NDIN 1444 with a January 28, 2026 response date.
- U.S. Food and Drug Administration, FDA 101: Dietary Supplements — explains that FDA does not approve dietary supplements for safety and effectiveness before sale.